Literature DB >> 29765265

Is volumetric modulated arc therapy with constant dose rate a valid option in radiation therapy for head and neck cancer patients?

Annamaria Didona1, Valentina Lancellotta2, Claudio Zucchetti3, Bianca Moira Panizza4, Alessandro Frattegiani4, Martina Iacco3, Anna Concetta Di Pilato3, Simonetta Saldi2, Cynthia Aristei2.   

Abstract

BACKGROUND: Intensity-modulated radiotherapy (IMRT) improves dose distribution in head and neck (HN) radiation therapy. Volumetric-modulated arc therapy (VMAT), a new form of IMRT, delivers radiation in single or multiple arcs, varying dose rates (VDR-VMAT) and gantry speeds, has gained considerable attention. Constant dose rate VMAT (CDR-VMAT) associated with a fixed gantry speed does not require a dedicated linear accelerator like VDR-VMAT. The present study explored the feasibility, efficiency and delivery accuracy of CDR-VMAT, by comparing it with IMRT and VDR-VMAT in treatment planning for HN cancer. METHODS AND MATERIALS: Step and shoot IMRT (SS-IMRT), CDR-VMAT and VDR-VMAT plans were created for 15 HN cancer patients and were generated by Pinnacle3 TPS (v 9.8) using 6 MV photon energy. Three PTVs were defined to receive respectively prescribed doses of 66 Gy, 60 Gy and 54 Gy, in 30 fractions. Organs at risk (OARs) included the mandible, spinal cord, brain stem, parotids, salivary glands, esophagus, larynx and thyroid. SS-IMRT plans were based on 7 co-planar beams at fixed gantry angles. CDR-VMAT and VDR-VMAT plans, generated by the SmartArc module, used a 2-arc technique: one clockwise from 182° to 178° and the other one anti-clockwise from 178° to 182°. Comparison parameters included dose distribution to PTVs (Dmean, D2%, D50%, D95%, D98% and Homogeneity Index), maximum or mean doses to OARs, specific dose-volume data, the monitor units and treatment delivery times.
RESULTS: Compared with SS-IMRT, CDR-VMAT significantly reduced the maximum doses to PTV1 and PTV2 and significantly improved all PTV3 parameters, except D98% and D95%. It significantly spared parotid and submandibular glands and was associated with a lower Dmean to the larynx. Compared with VDR-VMAT, CDR-VMAT was linked to a significantly better Dmean, to the PTV3 but results were worse for the parotids, left submandibular gland, esophagus and mandible. Furthermore, the Dmean to the larynx was also worse. Compared with SS-IMRT and VDR-VMAT, CDR-VMAT was associated with higher average monitor unit values and significantly shorter average delivery times.
CONCLUSIONS: CDR-VMAT appeared to be a valid option in Radiation Therapy Centers that lack a dedicated linear accelerator for volumetric arc therapy with variable dose-rates and gantry velocities, and are unwilling or unable to sanction major expenditure at present but want to adopt volumetric techniques.

Entities:  

Keywords:  Constant dose rate VMAT; Head and neck radiation therapy; Intensity modulated radiotherapy; Volumetric-modulated arc therapy

Year:  2018        PMID: 29765265      PMCID: PMC5948416          DOI: 10.1016/j.rpor.2018.02.007

Source DB:  PubMed          Journal:  Rep Pract Oncol Radiother        ISSN: 1507-1367


  19 in total

1.  Volumetric modulated arc therapy: IMRT in a single gantry arc.

Authors:  Karl Otto
Journal:  Med Phys       Date:  2008-01       Impact factor: 4.071

2.  Characterization of a novel 2D array dosimeter for patient-specific quality assurance with volumetric arc therapy.

Authors:  Sotirios Stathakis; Pamela Myers; Carlos Esquivel; Panayiotis Mavroidis; Nikos Papanikolaou
Journal:  Med Phys       Date:  2013-07       Impact factor: 4.071

3.  Variable dose rate single-arc IMAT delivered with a constant dose rate and variable angular spacing.

Authors:  Grace Tang; Matthew A Earl; Cedric X Yu
Journal:  Phys Med Biol       Date:  2009-10-09       Impact factor: 3.609

4.  Feasibility study of volumetric modulated arc therapy with constant dose rate for endometrial cancer.

Authors:  Ruijie Yang; Junjie Wang; Feng Xu; Hua Li; Xile Zhang
Journal:  Med Dosim       Date:  2013-05-10       Impact factor: 1.482

5.  Radiotherapy facilities, equipment, and staffing in Poland: 2005-2011.

Authors:  Marian Reinfuss; Edward Byrski; Julian Malicki
Journal:  Rep Pract Oncol Radiother       Date:  2013-03-13

6.  Static and rotational intensity modulated techniques for head-neck cancer radiotherapy: a planning comparison.

Authors:  Sara Broggi; Lucia Perna; Francesco Bonsignore; Giuseppe Rinaldin; Claudio Fiorino; Anna Chiara; Cristina Frigerio; Ivana Butti; Giulia Sangalli; Italo Dell'Oca; Nadia Di Muzio; Giovanni Mauro Cattaneo; Fausto Declich
Journal:  Phys Med       Date:  2014-08-10       Impact factor: 2.685

7.  A comparison of several modulated radiotherapy techniques for head and neck cancer and dosimetric validation of VMAT.

Authors:  Florian Stieler; Dirk Wolff; Heike Schmid; Grit Welzel; Frederik Wenz; Frank Lohr
Journal:  Radiother Oncol       Date:  2011-09-30       Impact factor: 6.280

8.  Volumetric intensity-modulated arc therapy vs. conventional IMRT in head-and-neck cancer: a comparative planning and dosimetric study.

Authors:  Wilko F A R Verbakel; Johan P Cuijpers; Daan Hoffmans; Michael Bieker; Ben J Slotman; Suresh Senan
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-05-01       Impact factor: 7.038

9.  Feasibility of constant dose rate VMAT in the treatment of nasopharyngeal cancer patients.

Authors:  Wenliang Yu; Haijiao Shang; Congying Xie; Ce Han; Jinling Yi; Yongqiang Zhou; Xiance Jin
Journal:  Radiat Oncol       Date:  2014-11-04       Impact factor: 3.481

10.  RapidArc, SmartArc and TomoHD compared with classical step and shoot and sliding window intensity modulated radiotherapy in an oropharyngeal cancer treatment plan comparison.

Authors:  Dirk Van Gestel; Corine van Vliet-Vroegindeweij; Frank Van den Heuvel; Wouter Crijns; Ann Coelmont; Bie De Ost; Andrea Holt; Emmy Lamers; Yasmyne Geussens; Sandra Nuyts; Danielle Van den Weyngaert; Tim Van den Wyngaert; Jan B Vermorken; Vincent Gregoire
Journal:  Radiat Oncol       Date:  2013-02-20       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.